Tratamiento de Verrugas Comunes Refractarias y Recurrentes

Escenario Clínico

Las verrugas comunes que no han respondido al tratamiento inicial, o que han recurrido tras un ciclo previo de manejo, representan un desafío clínico particular. Estos casos refractarios y recurrentes requieren un enfoque escalonado que va más allá del tratamiento estándar de primera línea.

Enfoque Terapéutico

El protocolo para este escenario se centra en la terapia de inyección intralesional local — agentes administrados directamente en el tejido de la verruga a intervalos estructurados. Múltiples agentes inyectables cuentan con evidencia que respalda su uso en este contexto refractario y recurrente.

Los agentes específicos, sus criterios de selección y el esquema de tratamiento se detallan en el protocolo estructurado completo.

Objetivo del Tratamiento

Eliminación completa de las verrugas a las 4 semanas.

Eliminación completa a las 4 semanas
Acceso Instantáneo a Regímenes Estructurados Basados en Evidencia

References

DOI: 10.1111/jebm.12494

Local injections with bleomycin, 5-Fluorouracil (5-FU), and cidofovir are suggested for refractory and recurrent common warts.

A case-series study showed that after an average of 2.61 treatment cycles with intralesional injection of bleomycin (therapeutic dose at 3 U/ml and treatment interval at 3–4 weeks), all of the 250 periungual and subungual warts in 80 patients of whom 26 (32.50%) patients were either with no response to or recurrence after previous treatments were cleared and 65 (81.25%) patients experienced moderate pain during the treatment sessions, 155 (62.00%) treatment sites had transit dyspigmentation, and 3 (1.20%) treatment sites experienced reversible necrosis.

A prospective study reported that the cure rate of common warts with the injection of 5-FU, lidocaine, and epinephrine mixture (50 mg/ml 5-FU plus with lidocaine and epinephrine mixture at a ratio of 4:1) was higher than that of saline control (64.70% vs. 35.30%, p<0.05).

The result showed that lesional injection with 15 mg/ml cidofovir once a month, on average of 3.2 sessions, cleared relapsed and refractory warts in 276 of 280 patients.

The clinical criteria for cure of warts are complete clearance of lesions at 4 weeks and no recurrence for at least 6 months.

View source ↗